Analysis

Astrazeneca Plc (AZN) Stock Analysis

Astrazeneca Plc investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to AZN.

websiteAZN/analysis/AZN

Astrazeneca Plc

Astrazeneca Plc investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to AZN.

Stock profile

Ticker

AZN

Asset type

Stock

Market cap

$269.38B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

GBX

Ticker listings

Astrazeneca Plc may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • AZN primary listing
  • ZEG
  • 886455
  • A1ZN34
  • AZNL
  • AZNN
  • AZN1N
  • AZND

Latest Astrazeneca Plc news

AstraZeneca Joins ZERO Prostate Cancer's Historic 'Blitz the Barriers' Initiative as a Founding Partner

ZERO Prostate Cancer, the nation's leading prostate cancer organization dedicated to advocacy, awareness, education, and support, today announced AstraZeneca has joined their gr...

AstraZeneca : Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy

AstraZeneca : Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitiv...

WILMINGTON, Del., June 12, 2026--AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted t...

AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardi...

AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney

Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026

BOSTON & SHANGHAI, June 01, 2026--Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026

Research sections

Valuation

Review valuation context for Astrazeneca Plc.

Future growth

Review future growth context for Astrazeneca Plc.

Past performance

Review past performance context for Astrazeneca Plc.

Financial health

Review financial health context for Astrazeneca Plc.

Dividend

Review dividend context for Astrazeneca Plc.

Management

Review management context for Astrazeneca Plc.

Ownership

Review ownership context for Astrazeneca Plc.

Other information

Review other information context for Astrazeneca Plc.

Community

Review community context for Astrazeneca Plc.